ABSTRACT
ABSTRACT Introduction: Acute promyelocytic leukemia currently presents an excellent chance of cure with protocols based on all-trans-retinoic acid (ATRA) and anthracycline or only differentiation agents. However, high early mortality rates continue to be reported Methods: Between 2000 and 2018, patients were enrolled and retrospectively analyzed by medical records. A modified AIDA protocol, with a 1-year shortening of the treatment duration, reduction in the number of drugs and a strategy to reduce early mortality by the postponement of the initiation of anthracyclines were employed. Overall and event-free survival rates and toxicity were analyzed Results: Thirty-two patients were enrolled, of whom 56% were female, with a median age of 12 years and 34% belonged to the high-risk group. Two patients had the hypogranular variant and three had another cytogenetic alteration, in addition to the t(15;17). The median start of the first anthracycline dose was 7 days. There were two early deaths (6%) due to central nervous system (CNS) bleeding. All patients achieved molecular remission after the consolidation phase. Two children relapsed and were rescued by arsenic trioxide and hematopoietic stem cell transplantation. The presence of disseminated intravascular coagulation (DIC) at diagnosis (p = 0.03) was the only factor with survival impact. The five-year event-free survival (EFS) was 84% and 5-year overall survival (OS) was 90% Conclusion: The survival results were comparable to those found in the AIDA protocol, with a low rate of early mortality in relation to the Brazilian reality.
ABSTRACT
INTRODUCTION: Acute promyelocytic leukemia currently presents an excellent chance of cure with protocols based on all-trans-retinoic acid (ATRA) and anthracycline or only differentiation agents. However, high early mortality rates continue to be reported METHODS: Between 2000 and 2018, patients were enrolled and retrospectively analyzed by medical records. A modified AIDA protocol, with a 1-year shortening of the treatment duration, reduction in the number of drugs and a strategy to reduce early mortality by the postponement of the initiation of anthracyclines were employed. Overall and event-free survival rates and toxicity were analyzed RESULTS: Thirty-two patients were enrolled, of whom 56% were female, with a median age of 12 years and 34% belonged to the high-risk group. Two patients had the hypogranular variant and three had another cytogenetic alteration, in addition to the t(15;17). The median start of the first anthracycline dose was 7 days. There were two early deaths (6%) due to central nervous system (CNS) bleeding. All patients achieved molecular remission after the consolidation phase. Two children relapsed and were rescued by arsenic trioxide and hematopoietic stem cell transplantation. The presence of disseminated intravascular coagulation (DIC) at diagnosis (pâ¯=â¯0.03) was the only factor with survival impact. The five-year event-free survival (EFS) was 84% and 5-year overall survival (OS) was 90% CONCLUSION: The survival results were comparable to those found in the AIDA protocol, with a low rate of early mortality in relation to the Brazilian reality.
ABSTRACT
Although frequently disseminated to other anatomical sites, neuroblastoma (NB) is rarely reported as involving the central nervous system (CNS), which may reflect insufficient research in poorly controlled systemic disease. Here we demonstrate the involvement of the CNS in patients with NB over 18 months of age at diagnosis of extensive systemic disease. Meningeal metastases were observed even in the presence of complete systemic control. Although no improvement in patient's survival was observed, radiotherapy was effective in preventing CNS recurrence after observation of actual or previous dural disease. In conclusion, this study uncovered the uncommon pathologic involvement of the CNS in children with advanced NB and underscores the meningeal surface as a potential pathway for this to occur.
Subject(s)
Central Nervous System/physiopathology , Neoplasm Recurrence, Local/prevention & control , Neuroblastoma/pathology , Neuroblastoma/radiotherapy , Skull Neoplasms/prevention & control , Child, Preschool , Humans , Infant , Meningeal Neoplasms/diagnosis , Meningeal Neoplasms/secondary , Neoplasm Metastasis , Prospective Studies , Radiotherapy , Skull Neoplasms/secondary , Treatment OutcomeABSTRACT
We describe the case of a 9-month old boy with unilateral retinoblastoma and bulftalmo. Primary enucleation was the treatment of choice due to the lack of visual prognosis. The histology of the enucleated eye showed massive choroidal invasion by the tumor and the optic nerve free of neoplastic tissue. Therefore, no adjuvant chemotherapy or radiotherapy was indicated. Three months after the enucleation, the patient returned with massive orbital retinoblastoma with exposure of the conjunctiva. Treated with chemotherapy, the patient has been in remission for 12 months. The risk factors for orbital recurrence are discussed.
Subject(s)
Orbital Neoplasms , Retinal Neoplasms , Retinoblastoma , Eye Enucleation , Humans , Infant , Male , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/therapy , Orbital Neoplasms/pathology , Orbital Neoplasms/therapy , Retinal Neoplasms/pathology , Retinal Neoplasms/therapy , Retinoblastoma/pathology , Retinoblastoma/therapy , Risk Factors , Treatment OutcomeABSTRACT
We describe the case of a 9-month old boy with unilateral retinoblastoma and bulftalmo. Primary enucleation was the treatment of choice due to the lack of visual prognosis. The histology of the enucleated eye showed massive choroidal invasion by the tumor and the optic nerve free of neoplastic tissue. Therefore, no adjuvant chemotherapy or radiotherapy was indicated. Three months after the enucleation, the patient returned with massive orbital retinoblastoma with exposure of the conjunctiva. Treated with chemotherapy, the patient has been in remission for 12 months. The risk factors for orbital recurrence are discussed.
Relatamos paciente de 9 meses de idade com buftalmo e retinoblastoma unilateral. O paciente foi tratado com enucleação primária devido à falta de prognóstico visual. O exame do olho enucleado mostrou invasão maciça de coroide e ausência de comprometimento do nervo óptico não sendo, portanto, submetido a tratamento adjuvante de quimioterapia ou de radioterapia. Três meses após a enucleação, o paciente apresentou-se com retinoblastoma orbitário volumoso com exposição da conjuntiva. Tratado com quimioterapia permanece em remissão após 12 meses. São discutidos os fatores de risco para a ocorrência da recidiva orbitária.
Subject(s)
Humans , Infant , Male , Orbital Neoplasms , Retinal Neoplasms , Retinoblastoma , Eye Enucleation , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/therapy , Orbital Neoplasms/pathology , Orbital Neoplasms/therapy , Risk Factors , Retinal Neoplasms/pathology , Retinal Neoplasms/therapy , Retinoblastoma/pathology , Retinoblastoma/therapy , Treatment OutcomeABSTRACT
Although children with osteosarcoma have a higher incidence of a 2nd malignancy than the general population, its development in the lung is rare. The few reported cases belong to examples of carcinomas. Here we present the case of a 13-year-old boy with a primary pulmonary adenocarcinoma diagnosed 3 years after the osteosarcoma diagnosis and present a review of the literature.
Subject(s)
Adenocarcinoma/pathology , Bone Neoplasms/pathology , Lung Neoplasms/pathology , Neoplasms, Second Primary/pathology , Osteosarcoma/pathology , Adenocarcinoma/genetics , Adolescent , Amino Acid Sequence , Genes, erbB-1/genetics , Humans , Lung Neoplasms/genetics , Male , Sequence DeletionABSTRACT
OBJECTIVE: To present the characteristics and treatment outcomes of patients with retinoblastoma. METHODS: A retrospective case series was conducted to review the records of all new patients diagnosed with retinoblastoma between 2003 and 2005. Eyes with early disease, or advanced disease with potential vision were treated with chemotherapy (carboplatin and etoposide) in conjunction with early local therapy (laser or cryo). Radiotherapy was used in cases where the disease did not respond to the above protocols or in recurrent cases. Eyes in the late stage of disease with no potential vision in the initial examination or eyes and where conservative treatment had failed were enucleated. RESULTS: In total, we reviewed 28 new cases of retinoblastoma, 15 of which were unilateral and 13 of which were bilateral (46%). These data correspond to a mean of 9.3 new cases per year (0.77 case/ month). The mean age at diagnosis was 33.8 months for unilateral cases, and 19.15 months for bilateral cases (p=0.015). Leucocoria was the major presenting symptom (75%). All but one patient with unilateral disease had the affected eye enucleated due to advanced disease (mean follow-up: 39.91 months). Among the 13 bilateral cases, 13 eyes (50%) were enucleated, 11 eyes (42.4%) were saved with chemotherapy in conjunction with local therapy and 2 eyes (7.6%) were saved using external beam radiotherapy (mean follow-up: 41.91 months). In unilateral and bilateral disease, pathology data revealed choroid involvement in 50% and 30%, respectively, and optic nerve invasion in 92% and 50%, respectively. CONCLUSION: In this population, retinoblastoma was diagnosed too late and most eyes were consequently enucleated. In cases with bilateral disease, half of the eyes were preserved.
Subject(s)
Retinal Neoplasms/therapy , Retinoblastoma/therapy , Brazil , Child, Preschool , Epidemiologic Methods , Female , Hospitals, University , Humans , Infant , Male , Retinal Neoplasms/diagnosis , Retinoblastoma/diagnosisABSTRACT
OBJECTIVE: To present the characteristics and treatment outcomes of patients with retinoblastoma. METHODS: A retrospective case series was conducted to review the records of all new patients diagnosed with retinoblastoma between 2003 and 2005. Eyes with early disease, or advanced disease with potential vision were treated with chemotherapy (carboplatin and etoposide) in conjunction with early local therapy (laser or cryo). Radiotherapy was used in cases where the disease did not respond to the above protocols or in recurrent cases. Eyes in the late stage of disease with no potential vision in the initial examination or eyes and where conservative treatment had failed were enucleated. RESULTS: In total, we reviewed 28 new cases of retinoblastoma, 15 of which were unilateral and 13 of which were bilateral (46 percent). These data correspond to a mean of 9.3 new cases per year (0.77 case/ month). The mean age at diagnosis was 33.8 months for unilateral cases, and 19.15 months for bilateral cases (p=0.015). Leucocoria was the major presenting symptom (75 percent). All but one patient with unilateral disease had the affected eye enucleated due to advanced disease (mean follow-up: 39.91 months). Among the 13 bilateral cases, 13 eyes (50 percent) were enucleated, 11 eyes (42.4 percent) were saved with chemotherapy in conjunction with local therapy and 2 eyes (7.6 percent) were saved using external beam radiotherapy (mean follow-up: 41.91 months). In unilateral and bilateral disease, pathology data revealed choroid involvement in 50 percent and 30 percent, respectively, and optic nerve invasion in 92 percent and 50 percent, respectively. CONCLUSION: In this population, retinoblastoma was diagnosed too late and most eyes were consequently enucleated. In cases with bilateral disease, half of the eyes were preserved.
Subject(s)
Child, Preschool , Female , Humans , Infant , Male , Retinal Neoplasms/therapy , Retinoblastoma/therapy , Brazil , Epidemiologic Methods , Hospitals, University , Retinal Neoplasms/diagnosis , Retinoblastoma/diagnosisABSTRACT
Os hemangiomas sao anomalias muito frequentes na faixa etaria pediatrica e apresentam como principal caracteristica o potencial da involucao espontanea. O tratamento destas lesoes ainda e...
Subject(s)
Humans , Male , Female , Adrenal Cortex Hormones , Hemangioma , Neoplasms, Vascular Tissue , Hemangioma , Interferons , Prednisone , Prospective StudiesABSTRACT
De janeiro de 1980 a dezembro de 1984, 22 pacientes portadores de linfomas nao Hodgkin estadios III foram admitidos ao Instituto da Crianca-HC-FMUSP para tratamento segundo o Protocolo LNH-I-80, que se constituiu de uma fase de inducao de remissao (ciclofosfamida, Vincristina, Daunomicina e Prednisona), seguida por 72 semanas de manutencao (Ciclofosfamida, Adrimicina, Aracytin, Vincristina, Mercaptopurina, Methotrexate). Dos 22 pacientes, 21 entraram em remissao, um foi a obito em decorrencia de infeccao e seis recidivaram, dentre os quais cinco tinham linfomas de Burkitt. O protocolo empregado foi eficaz para pacientes com linfomas nao Burkitt, mas insuficiente para os portadores de linfomas Burkitt.
